Drug interactions
Armodafinil + Selumetinib
Severity: Moderate
Armodafinil and Selumetinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Armodafinil may lower selumetinib concentrations through CYP3A4 induction. Reduced exposure may decrease control of plexiform neurofibromas. Labeling advises avoiding strong and moderate CYP3A4 inducers.
What this interaction means in plain words
Armodafinil and Selumetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Armodafinil belongs to Central Nervous System; Selumetinib belongs to Oncology.
Why it happens
CYP3A4 induction by armodafinil increases the metabolism of selumetinib.
What to do
Prefer a non-inducing alternative to armodafinil. If coadministered, monitor tumor response and tolerability.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Armodafinil and Selumetinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Armodafinil
Other interactions of Selumetinib
Frequently asked questions
Can I take Armodafinil with Selumetinib?
MediHelp rates the interaction as moderate. Armodafinil and Selumetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Armodafinil may lower selumetinib concentrations through CYP3A4 induction. Reduced exposure may decrease control of plexiform neurofibromas. Labeling advises avoiding strong and moderate CYP3A4 inducers.
How serious is the interaction between Armodafinil and Selumetinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer a non-inducing alternative to armodafinil. If coadministered, monitor tumor response and tolerability.
What other medicines interact with Armodafinil?
MediHelp also lists interactions of Armodafinil with, for example, Avapritinib, Elacestrant, Elbasvir / grazoprevir. The full list is on the Armodafinil page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
